Skip to content

Outcomes Of High Flow Nasal Cannula In Covid Pneumonia

Rox Index For Predicting Outcomes Of High Flow Nasal Cannula In Covid Pneumonia - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/088044
Enrollment
50
Registered
2025-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: HFNC: High flow will be provided with the Optiflow nasal cannula
Fisher & Paykel Healthcare, Auckland, New Zealand) with Airvo 2 (Fisher & Paykel Healthcare, Auckland. HFNC will be initiated with a minimum flow of 30L/min with a fraction of inspired oxygen (FiO2) o

Sponsors

Medanta Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients who are more than 18 yrs. old with hypoxemic respiratory failure due to COVID-19 pneumonia

Exclusion criteria

Exclusion criteria: 1. Patients younger than 18 years old, patients with indication for immediate intubation. 2. Patients for whom HFNC will be used for extubation failures and those with do-not-intubate order will be excluded. 3. Patients who will be electively intubated for diagnostic or therapeutic procedures (bronchoscopy, surgery) will not be included.

Design outcomes

Primary

MeasureTime frame
To assess the ROX index as a predictor of success of HFNC therapy for hypoxemic respiratory failure in COVID19 pneumoniaTimepoint: SOFA (10) score will be recorded once a day during the first five days of HFNC therapy. We will also record the 4C COVID mortality score. (11) Clinical respiratory variables in patients 2h, 6h, 12h, 18h, and 24h after initiation of HFNC therapy will be recorded. After the first 24 hours, the same variables will be recorded once daily until HFNC withdrawal

Secondary

MeasureTime frame
To assess the relation between ROX index & ICU stay, hospital stay, & outcomes of patientsTimepoint: SOFA (10) score will be recorded once a day during the first five days of HFNC therapy. We will also record the 4C COVID mortality score. (11) Clinical respiratory variables in patients 2h, 6h, 12h, 18h, & 24h after initiation of HFNC therapy will be recorded. After the first 24 hours, the same variables will be recorded once daily until HFNC withdrawal

Countries

India

Contacts

Public ContactRajesh Chandra

Medanta Hospital

doctor.harish@outlook.com9471300943

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026